$6.57
-0.33-4.78%
al cierre: Nov 17, 4:00 PM EST
$6.57
N/A
After hour: 4:00 PM EST

The average analyst price target for MapLight Therapeutics is $32.18, 389.8% above the current price. Of 12 analysts, 10 rate it Buy and 2 Hold. Targets range from $13 to $46. The latest change came on Oct 6, 2026, when Guggenheim initiated coverage of MapLight Therapeutics with a Neutral rating.
Price Target Range — 5 Quarters
Analyst Consensus — 12 Analysts
Rating Trend — Last 9 Months